PARSIPPANY, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. ("Sio") today announced that it expects to file a certificate of dissolution (the "Certificate of Dissolution") with the Secretary of State of the State of Delaware, as contemplated by the Plan of Complete Liquidation and Dissolution (the "Plan") previously approved by Sio's Board of Directors and stockholders, on February 7, 2024. The Certificate of Dissolution, which is expected to become effective at 4:00 p.m. Eastern Time on February 7, 2024 (the "Effective Time"), provides for the dissolution of Sio under the General Corporation Law of the State of Delaware (the "DGCL"). In connection with the filing of th

–  Three-Month and Nine-Month Losses decline by 84.2% and 73.5%, respectively –  Operating Cash Outflows for the Nine Months Ended December 31, 2022 decreased by $23.8 million or 56% versus the prior year period –  $46.1 million of cash and cash equivalents as of December 31, 2022, a strong cash position as the Company prepares for liquidation and dissolution, subject to stockholder approval NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today provided financial results for its fiscal third quarter ended December 31, 2022. "Our financial results continue to show the beneficial effects on operating expenses and cash burn resulting from the termination

NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today announced that its Board of Directors has determined, after extensive and careful consideration of potential strategic alternatives, that it is in the best interests of the Company and its shareholders to dissolve the Company and liquidate its assets, including its subsidiaries. "After evaluating the Company's strategic options, the Board of Directors unanimously concluded that it is in the best interests of the shareholders to dissolve and liquidate the Company," stated David Nassif, Chief Executive Officer. "The Board of Directors and management, together with its external advisors, devoted substanti

HC Wainwright & Co. reiterated coverage of Sio Gene Therapies with a rating of Buy and set a new price target of $7.00 from $10.00 previously

SVB Leerink downgraded Sio Gene Therapies from Outperform to Market Perform and set a new price target of $1.00 from $6.00 previously

HC Wainwright & Co. reiterated coverage of Sio Gene Therapies with a rating of Buy and set a new price target of $10.00 from $8.00 previously

4 - Sio Gene Therapies Inc. (0001636050) (Issuer)

4 - Sio Gene Therapies Inc. (0001636050) (Issuer)

3 - Sio Gene Therapies Inc. (0001636050) (Issuer)

15-12G - Sio Gene Therapies Inc. (0001636050) (Filer)

EFFECT - Sio Gene Therapies Inc. (0001636050) (Filer)

POS AM - Sio Gene Therapies Inc. (0001636050) (Filer)

Consistent dose-dependent improvements across biomarker measuresNormalization of serum beta-galactosidase activity and GM1 ganglioside in CSF in the high-dose cohort No overt disease progression in six out of seven patients treated across low- and high-dose cohorts Total of ten patients have received gene therapy to date without SAEs attributable to AXO-AAV-GM1 Management to host conference call and webcast today, October 21, at 8:30 a.m. EDT NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today pres

- Company had $81 million of cash and cash equivalents as of December 31, 2020, and expects to receive additional $16 million in cash in 2021 from sale of Arvelle Therapeutics shares - Cash runway expected into the second calendar quarter of 2022 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today provided financial results for its third fiscal quarter ended December 31, 2020. “In recent months, Sio Gene Therapies has made important progress in advancing its patient-fo

SC 13G/A - Sio Gene Therapies Inc. (0001636050) (Subject)

SC 13G - Sio Gene Therapies Inc. (0001636050) (Subject)

SC 13G/A - Sio Gene Therapies Inc. (0001636050) (Subject)